Regenerative Medicine to reverse bone-loss
Mesentech developed a novel drug conjugate that can deliver medicines selectively to the bone. Our first drug candidate, MES1007, reverses bone loss.
A Bone targeting platform to treat rare bone-diseases
Mesentech's bone anabolic drug conjugates will be incrementally developed as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis.
Stepping Stones to The Future of Bone Regeneration
A topical formulation is being developed as a bone graft material to speed osseointegration in orthopedic and oral-maxillofacial indications while avoiding the cost and morbidity associated with harvesting self-donor material for autografts.
Regenerative Medicine to reverse bone-loss
Mesentech developed a novel drug conjugate that can deliver medicines selectively to the bone. Our first drug candidate, MES1007, reverses bone loss.
